Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. - Wikidata - awgldk - TriplyDB

Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.

Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.

http://www.wikidata.org/entity/Q36109889

about

β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature Metabolic syndrome in children with chronic kidney disease and after renal transplantation Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.Anti-hypertensive drugs in children and adolescents Antihypertensive drugs and glucose metabolism Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities Abnormal aldosterone physiology and cardiometabolic risk factors.Diabetes mellitus and vascular disease Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension Peripheral adrenoceptors: the impetus behind glucose dysregulation and insulin resistance.β-Adrenergic blockade in cardiovascular disease.A Comparison of Vasodilating and Non-vasodilating Beta-Blockers and Their Effects on Cardiometabolic Risk.Cardiac salvage by tweaking with beta-3-adrenergic receptors.Novel insight into the dangerous connection between diabetes and heart failure.Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.New and Emerging Therapies and Targets: Beta-3 Agonists.Insulin and β Adrenergic Receptor Signaling: Crosstalk in Heart.A review of chemical therapies for treating diabetic hypertension.Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.Singular and combined effects of nebivolol and lifestyle modification on large artery stiffness in hypertensive adults.Nebivolol, But Not Metoprolol, Treatment Improves Endothelial Fibrinolytic Capacity in Adults With Elevated Blood Pressure.Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans.The Vasculature in Prediabetes.Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F2α.Insights on β-blockers for the treatment of hypertension: A survey of health care practitioners

P2860

Q26861630-C05F5964-6F38-49D2-9A76-BBB912610D10 Q27027049-552B3438-1C35-466C-BD3F-E864046E5F1F Q30491698-D2D00C71-DE93-4BAF-94B8-66CC9E45C9BD Q33772773-638C3D6C-C04A-49DF-A251-8569EC32B5E1 Q33948469-580663A8-BB2A-44EC-8B41-A63D9653C4DC Q35945451-FC7224C2-D5D6-404E-9AAB-34D47464B1D6 Q36400253-F1394AD3-386E-49AE-81BE-02C52A159188 Q36737227-D1B1370C-464C-43D9-82F9-259121A10F1A Q36829126-E63F1535-E9B1-41E1-859B-4ED862F16C39 Q37238488-2E1FD426-2F02-4659-8ECC-CF9D9D8C3D45 Q38058833-B5F7614E-B6AC-4B15-8EC4-807D1CEF8179 Q38103516-420AFAE2-DAF7-4429-B258-1298FE45C3D7 Q38433805-A65FE3F0-5C40-4BF2-AC6D-54332975ADC9 Q38784206-595889E8-A3D0-4919-86D4-68A0D1E74457 Q38806574-C58AF909-697A-4EFA-B60C-B25411329DFB Q38913816-6F04A726-A436-48D8-BC50-98849BB67F78 Q39062830-30A240ED-5E35-4598-BF4D-98630BD05B79 Q39159635-890BB08C-7211-44FC-8202-71BAC662866F Q39290260-B16C4003-6D84-40CC-AE1A-AEB105C970F1 Q39717221-3F523D15-5936-4D63-9FD5-302D62C77FA0 Q44990862-D203BEDA-1651-4B6F-B03B-0FEC27260CC2 Q47120708-C86D7E44-5C9A-4E48-935A-EAD8F7E6547F Q47931514-19A25E55-FD70-4CC4-BAEB-62F898961E06 Q53695913-7FB7D7A6-525B-4576-804C-C9636BC11A9D Q54235357-EE28EE40-69E5-401E-84E8-6E674435F41B Q55279804-9E3D4D0A-D61C-4D33-8077-6ACA8335230D Q56981925-97F9C63B-6B24-4FD6-8913-E3E38F0E76B8

P2860

Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.

http://www.wikidata.org/entity/Q36109889

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Differential effects of nebivo ...... tor in the metabolic syndrome.

@ast

Differential effects of nebivo ...... tor in the metabolic syndrome.

@en

type

label

Differential effects of nebivo ...... tor in the metabolic syndrome.

@ast

Differential effects of nebivo ...... tor in the metabolic syndrome.

@en

prefLabel

Differential effects of nebivo ...... tor in the metabolic syndrome.

@ast

Differential effects of nebivo ...... tor in the metabolic syndrome.

@en

P1433

Q36109889-0BE681B9-D1DD-46DB-A62D-ED6B52CF2918

P1476

Q36109889-E76A9C11-21ED-4539-BF7E-BC0367CD0D03

P2093

Q36109889-7DEA77EF-894B-47CB-86CD-49FC8DA1C488

Q36109889-7E6BCDEB-FC5F-4373-BD31-B4F2F289C50A

Q36109889-A0D3E0B8-D3DF-44DD-B3E6-D9036E3384C5

Q36109889-AB2E687A-46BC-4C7B-BA59-FA9B38D904FC

P2860

Q36109889-00EAA7F2-A323-4C9C-9B4E-ED73BCF18076

Q36109889-074168A9-8E6F-40B1-9F78-A8522872FEAF

Q36109889-0BE284B1-AC02-4917-88CD-0FE1AE089457

Q36109889-1444ACC5-BEB6-4333-A8A1-1F06C152B3B0

Q36109889-1E96BA8B-2521-46FA-AEE4-61A9E0CFF6AC

Q36109889-1FA353DA-E435-4D5A-99E5-831CDF03ED05

Q36109889-2B848C91-F64A-45FC-8A88-33F97DB618FC

Q36109889-2C25DEB0-FE8B-408D-9CE8-7FF2F10CD384

Q36109889-3810BBE5-DDD2-4DDE-8258-4AD1B8743FC0

Q36109889-39B9B1A1-BA27-439A-BA20-B0135089F6FA

P304

Q36109889-4744DBAF-76A1-40BF-9993-5768925698FF

P31

Q36109889-81F8A11A-E5B6-4C80-B6F5-65DE9B0FA786

P356

Q36109889-28B325FC-2B2C-4051-A46D-2DDC70883165

P407

Q36109889-FC43D136-8D12-44A0-8607-65FC50D92BC0

P433

Q36109889-A6072DD9-5539-44DA-819D-AAEE45CD4568

P478

Q36109889-97859042-6F9D-43D6-8587-6A58D659251F

P577

Q36109889-7C044670-B264-463F-BCB3-52A4A9E4B1ED

P698

Q36109889-286CB2C9-8010-4BC0-A3BF-F9433B32E48F

P932

Q36109889-0E66C56B-7CD5-403A-BAEC-1634254FF8EB

P356

HYPERTENSIONAHA.111.189589

P1433

P1476

Differential effects of nebivo ...... tor in the metabolic syndrome.

@en

P2093

Anthony DeMatteo

http://www.w3.org/2001/XMLSchema#string

Katie Ayers

http://www.w3.org/2001/XMLSchema#string

Loretta M Byrne

http://www.w3.org/2001/XMLSchema#string

Nancy J Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients

Effect of valsartan on the incidence of diabetes and cardiovascular events

Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system

A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.

MERIT-HF mortality and morbidity data.

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.

Effect of ramipril on the incidence of diabetes.

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.

Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans.

The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension.

P304

893-898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HYPERTENSIONAHA.111.189589

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22353614

http://www.w3.org/2001/XMLSchema#string

P932

3402551

http://www.w3.org/2001/XMLSchema#string